CD8A and cancer: An interesting multicentre meta-analysis from the previous year indicates that a reduction of the risk of cancer death among patients treated for HNSCC is significantly related to the presence of large CD4+ TILs (HR 0.77; 95% CI: 0.65–0.93) and CD8+ (HR 0.64; 95% CI: 0.47–0.88) subpopulations [63].